Is Cohu (COHU) Still Below Fair Value Following Earnings And Sales Guidance?
Cohu (COHU) reported 2Q 2026 sales of $149 million and a much smaller net loss on July 30, and issued new 3Q sales guidance. Simply Wall St cites a fair value of $60.29 versus a $52.88 close, while its DCF estimate is $33.82. The article highlights valuation and risks tied to cyclical end markets and test-platform qualification.
How this was made
The 30-second read
Why it matters
For traders, the article is mainly a valuation narrative around already-reported earnings and guidance, with no additional disclosed guidance figures or new company-specific events beyond the fact that guidance was issued.
Market read
The market relevance is the existence of updated Q3 sales guidance and the subsequent debate on whether the stock is undervalued or overvalued, but the article does not add new decision-grade numbers.
What to watch
The piece flags dependence on cyclical end markets and timely qualification of AI/HPC test platforms, which could dominate near-term fundamentals regardless of DCF assumptions.
Background
Simply Wall St discusses Cohu’s Q2 2026 results and new Q3 sales guidance from July 30, then frames the stock’s move using “fair value” versus a DCF model.
Ticker impact
Cohu reported Q2 results and issued new Q3 sales guidance, then the article debates whether the post-earnings rerating leaves shares below or above fair value.
Near-term price action likely remains driven by how the market interprets the Q3 sales guidance versus the valuation debate, with limited incremental impact from this article alone.
The text confirms earnings and guidance occurred, but it does not provide the specific Q3 guidance figures or any fresh post-release datapoint beyond valuation model comparisons.
Market effects
Reinforces the chip testing and automation theme tied to higher-margin recurring software, but provides no new sector-wide catalyst.
None stated.
None stated.
Counterpoint
The article highlights conflicting valuation outputs (fair value $60.29 vs DCF value $33.82), implying the rerating may be fragile if cyclical end markets or platform qualification timelines slip.
Key entities
- companyCohu
US chip testing and related technologies company that reported Q2 results and provided Q3 sales guidance; the article evaluates whether the post-earnings rerating is justified.